Reregulation of cortisol levels and sleep in patients with prescription opioid use disorder during long-term residential treatment
| Autor: | Dean Stankoski, Edward O. Bixler, Andrew S. Huhn, Christopher S. Freet, Scott C. Bunce, Erin Deneke, Roger E. Meyer, Dahlia Mukherjee, Lan Kong, Sarah E. Tilden |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Hydrocortisone media_common.quotation_subject Pituitary-Adrenal System Toxicology Basal (phylogenetics) Internal medicine medicine Humans Pharmacology (medical) In patient Medical prescription Saliva Residential Treatment Cortisol level media_common Pharmacology business.industry Actigraphy Opioid use disorder Abstinence Opioid-Related Disorders medicine.disease Sleep in non-human animals Psychiatry and Mental health Prescriptions Sleep business |
| Zdroj: | Drug and Alcohol Dependence. 227:108931 |
| ISSN: | 0376-8716 |
| Popis: | Objective Research has demonstrated that hypothalamic-pituitary-adrenal (HPA) axis function and sleep patterns are dysregulated in patients diagnosed with opioid use disorder (OUD). It is unclear whether and/or when cortisol and sleep might re-regulate over time, and, whether re-regulation is associated with abstinence following discharge from residential treatment. The current study evaluated changes in sleep and basal cortisol levels in prescription OUD patients in residential treatment, and the association between these measures and treatment outcome following discharge. Method As part of a larger study, 55 participants with prescription OUD provided two days of salivary cortisol samples and 12 consecutive nights of sleep actigraphy between days 19–30 of residential treatment (Time Point 1; TP1). Thirteen of the original 55 participants remained in residence and repeated the measures between days 60–72 (Time Point 2; TP2). Thirty-seven healthy controls (HC) provided baseline measures (TP1) of salivary cortisol and sleep. Treatment outcome data, abstinence vs relapse, were established at 120 days following discharge. Results Prescription OUD patients had higher cortisol levels and lower total sleep time (TST) than HC at TP1. At TP2, TST and cortisol levels no longer differed from HCs in the subgroup of patients who remained abstinent following discharge after TP2. Individuals whose cortisol and TST did not change from TP1 to TP2 were more likely to relapse following discharge from residential treatment. Conclusion Re-regulation of TST and cortisol levels while in residential treatment was associated with better treatment outcome following discharge for prescription OUD patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect